Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, September 27, 2011 Biosign CEO Demonstrates Cloud Dx(TM) Solution at Health 2.0 Conference
SAN FRANCISCO, Sept. 27, 2011 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) a medical device company focused on non-invasive, cloud-based vital health monitoring, sponsored the "In Conversation with 3 CEO's" panel featuring Anne Wojcicki of 23andme, Sona Mehring of Caring Bridge, and West Shell of Healthline at the Health 2.0 Conference. Biosign, CEO, Dr. Scott Jenkins is scheduled to introduce the panel to over 1,000 attendees and demonstrate the Cloud DxTM solution that enables providers to deliver quality care utilizing the UFIT® device and remote cloud monitoring systems.
Health 2.0 is known for showcasing innovative healthcare technology and bringing together the industry's top thought leaders. Biosign was invited as 1 of 10 businesses to meet with key investors and decision makers at healthcare organizations, like United Health Group, California Health Care Foundation, Interwest Partners, the U.S. Government, and AT&T ForHealthSM to discuss the Cloud DxTM solution.
"It was an honor to be selected in the first ever Matchpoint! at Health 2.0. Considering the criteria for selection indicated an interest in investment, partnering or pilots - this is a very exciting time for us as a company," said Dr. Jenkins, CEO, Bisosign.
UFIT® combines the power of the cloud for validation and analysis with an easy to use wrist cuff for pain-free non-invasive measurement of vital health information. Measuring both blood glucose and blood pressure from a single device makes this application unique. Biosign offers additional data analysis services through their Cloud DxTM solution.
Biosign agreed to provide the opportunity for anyone attending Health 2.0 to take their own readings at a special station. The device is not yet approved by the FDA for sale in the U.S., but allowing people to experience how the UFIT® medical device works is the first step to getting the disruptive but necessary Cloud DxTM solution into the hands of patients and doctors.
About Cloud DxTM
The Cloud DxTM brand is a trademark of Biosign Technologies Inc. under which Biosign delivers services to consumers, healthcare professionals and payers. Biosign collects data from proprietary non-invasive devices, uses the cloud for validation, analysis and synthesis of the data, and then makes the information available to patients and their Circle of CareTM. We believe Cloud DxTM is the future of remote healthcare monitoring and quality patient care. For more information, please visit: [ www.1000billionreasons.com ] and [ www.clouddx.com ].
About Biosign Technologies Inc
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems through its Cloud DxTM branded solution. Cloud DxTM applications include intelligent systems for non-invasive monitoring of common health risks associated with blood pressure, glucose, and medication. Biosign technology combines measurement, analysis, and tools for disease and patient management to support global vital health monitoring. The UFIT® medical device delivers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation and management, and remote patient monitoring. For more information visit: [ www.biosign.com ].
Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators ([ www.sedar.com ]).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
